Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
Presentation by Camille Lombard-Banek, NIST: Expending MAM Principles to the Characterization of Cell-based Therapies
Loading view.
USP Biologics Open Forum on MAM
USP Biologics Open Forum on MAM
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Rich Rogers, BMS: Mass Spectrometry-Based Process Analytical Technologies for Cell Therapies
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the benefits of New Peak Detection
Presentation by Silvia Millán Martín, NIBRT: The role of MAM in advancing innovative analytical strategies for biotherapeutics characterization and the…
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes
Presentation by Mitul Patel, GSK: Incorporating Mass Spectrometry into Analytical Strategies to Early De-risk the mAb Discovery and CMC processes
Presentation by Adam Evans, Janssen: Multi-Attribute Monitoring from Development to Commercial QC
Presentation by Adam Evans, Janssen: Multi-Attribute Monitoring from Development to Commercial QC
Presentation by Diane McCarthy, US Pharmacopeia: USP Standards to Support Multi-Attribute Methods
Presentation by Diane McCarthy, US Pharmacopeia: USP Standards to Support Multi-Attribute Methods
Presentation by John Schiel, NIST, Mass Spectrometry as a Disruptive Technology for Emerging Modalities
Presentation by John Schiel, NIST, Mass Spectrometry as a Disruptive Technology for Emerging Modalities
Presentation by Pavel Bondarenko, Amgen, Identification of Critical Chemical Modifications and Paratope Mapping by SEC of Stressed Antibody-target Complexes
Presentation by Pavel Bondarenko, Amgen, Identification of Critical Chemical Modifications and Paratope Mapping by SEC of Stressed Antibody-target Complexes
MAM Consortium Presentation by Andrew Mahan, Janssen: Comprehensive Characterization of mAbs and Multispecifics with Multiple Technologies, CE, iCIEF-MS and Novel Alternative Fragmentation
MAM Consortium Presentation by Andrew Mahan, Janssen: Comprehensive Characterization of mAbs and Multispecifics with Multiple Technologies, CE, iCIEF-MS and Novel…